Study of the Role of Genetic Modifiers in Hemoglobinopathies
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age2+
SponsorCyprus Institute of Neurology and Genetics
About this trial
This study will investigate the role of genetic modifiers in hemoglobinopathies through a large-scale, multi-ethnic genome-wide association study (GWAS).
Eligibility criteria
Qualifiers
Clinical diagnosis of an inherited hemoglobinopathy, including sickle cell disease (SCD), β-thalassemia, and α-thalassemia; all genotypes will be considered.
Age ≥ 2 years old at the time of the collection of the phenotypic data.
There will be no limits on study participants in terms of gender, ethnicity, morbidities.
Disqualifiers
Patients treated with stem cell transplantation or genetic therapy.
Age < 2 years old at the time of the collection of the phenotypic data.
Patient or legal representative for minors unwilling or unable to give consent.
Trial design
Treatments tested in this trial
- GWAS
Treatment groups
30,000 Participants
are divided into 1 treatment groupLocations
26Angola
Lucrecia Paím Maternity Luanda Angola
Argentina
University of Buenos Aires Buenos Aires Argentina
Belgium
University Hospitals Leuven Leuven Belgium
Brunei
Universiti Brunei Darussalam Brunei Brunei
Sponsors and collaborators
Cyprus Institute of Neurology and Genetics
Lead sponsor
Source ClinicalTrials.gov